AuNCs–LHRHa nano-system for FL/CT dual-mode imaging and photothermal therapy of targeted prostate cancer. Issue 27 (20th June 2022)

• Record Type: Journal Article
• Authors: Wang, Ze; He, Liang; Che, Songtian; Xing, Huiyuan; Guan, Lin; Yang, Zhe; Li, Xingchen; Zvyagin, Andrei V.; Lin, Quan; Qu, Wenrui
• Is Part Of: Journal of materials chemistry. Volume 10:Issue 27(2022)
• Page Start: 5182
• Page End: 5190
• Publication Date: 2022-06-20
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/d2tb00531j
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : The AuNCs-LHRHa nano-system, which combines dual-mode imaging and targeted therapy, will provide a promising strategy for the integration of FL/CT diagnosis and PTT therapy for GnRH-R positive prostate cancer. Abstract : As the most common cancer in men worldwide, prostate cancer has a serious impact on people's health. Until now, the development of a platform for integrating tumor targeting, imaging and an effective treatment for prostate cancer has remained challenging. Herein, a nano-system is designed to improve both diagnosis and treatment for prostate cancer. We successfully synthesized an AuNCs–LHRHa nano-system by combining PEI-modified gold nanoclusters (AuNCs) with LHRH analogues (LHRHa). Due to the good tunable optical properties and photothermal properties of AuNCs, the nano-system can not only achieve efficient fluorescence/computed tomography dual-mode imaging, but can also be used for photothermal therapy (PTT). After modifying the LHRHa antibody of a prostate tumor, AuNCs–LHRHa can be more effectively recognized by the gonadotropin-releasing hormone receptors (GnRH-R) on the membrane of RM-1 cells, enhancing the tumor cell uptake of the nano-system, improving the targeting accuracy and PTT therapy efficacy for prostate cancer. It is hoped that the nano-system, which combines dual-mode imaging and targeted therapy, will provide a promising strategy for the integration of FL/CT diagnosis and PTT therapy for GnRH-R positive prostate cancer.